Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review

BACKGROUND: Resistant chronic migraine is a highly disabling condition which is very difficult to treat. The majority of the treatments for migraine prophylaxis are nonspecific and present weak safety profiles, leading to low adherence and discontinuation. Currently, monoclonal antibodies (mAb) targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sevivas, Hugo, Fresco, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167529/
https://www.ncbi.nlm.nih.gov/pubmed/35659086
http://dx.doi.org/10.1186/s40001-022-00716-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167529/
https://www.ncbi.nlm.nih.gov/pubmed/35659086
http://dx.doi.org/10.1186/s40001-022-00716-w

Ejemplares similares